Nuclein, LLC
4 additional officers and directors
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- 1 investornamed
1 investor on record.
The investors already on the cap table shape who leads the next round.
- 7 directorsboard
7 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 1
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 1
Financing history
- Jan 23, 2025Form D equity offering · $750,000 (form d sold) · 3 investorsFact Form D · “Nuclein, LLC filed Form D: $750,000 sold of $15,000,000, Biotechnology”
Investors on record
- Trinity Investors Fund Advisors, LLC board only, Sanjay Chandra (strongly supported) Inference sec.gov
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.No firm portfolio page lists this company, so no outcome is stated.
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- Alan Blake Executive Officer/Director sec.gov
- Jeffrey David Stukuls Executive Officer sec.gov
- Sanjay Chandra Director Inference
- William Cunningham Director Fact
- Richard Crockett Director Fact
Timeline
Evidence
Every observation on this company
- Entity type: Limited Liability Company Feb 5, 2026 Fact Form D
- Entity type: Limited Liability Company Feb 3, 2025 Fact Form D
- Form D industry group: Biotechnology Feb 5, 2026 Fact Form D
- Form D industry group: Biotechnology Feb 3, 2025 Fact Form D
- Amendment: true Feb 5, 2026 Fact Form D
- Amendment: false Feb 3, 2025 Fact Form D
- Revenue range (Form D): Decline to Disclose Feb 5, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Feb 3, 2025 Fact Form D
- Incorporated: overFiveYears Feb 5, 2026 Fact Form D
- Incorporated: overFiveYears Feb 3, 2025 Fact Form D
- Jurisdiction: Texas Feb 5, 2026 Fact Form D
- Jurisdiction: Texas Feb 3, 2025 Fact Form D
- Amount sold (Form D): $9.4M Feb 5, 2026 Fact Form D
- Amount sold (Form D): $750,000 Feb 3, 2025 Fact Form D
- Offering amount (Form D): $15.0M Feb 5, 2026 Fact Form D
- Offering amount (Form D): $15.0M Feb 3, 2025 Fact Form D
- Exemptions: 06b Feb 5, 2026 Fact Form D
- Exemptions: 06b Feb 3, 2025 Fact Form D
- First sale: 2025-01-23 Feb 5, 2026 Fact Form D
- First sale: 2025-01-23 Feb 3, 2025 Fact Form D
- Investors (Form D): 34 Feb 5, 2026 Fact Form D
- Investors (Form D): 3 Feb 3, 2025 Fact Form D
- Minimum investment (Form D): 0 Feb 5, 2026 Fact Form D
- Minimum investment (Form D): 0 Feb 3, 2025 Fact Form D
- Securities offered: equity Feb 5, 2026 Fact Form D
- Securities offered: equity Feb 3, 2025 Fact Form D
- Office address: Feb 5, 2026 Fact Form D
- Office address: Feb 3, 2025 Fact Form D
Relationships across DFX
on 1 other DFX graph
Nuclein, LLC is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Form D filed2026-02-05source on record
- Form D filed2025-02-03source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.